254 related articles for article (PubMed ID: 16755180)
1. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
[TBL] [Abstract][Full Text] [Related]
2. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
3. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A; Gattuso D; Stani SC; Fanelli M; Ferraù F; De Sio L; Castellana MA; Lorusso V; Priolo D; Vitale S; Sarmiento R; Lo Vullo S; Mariani L; Gasparini G
Breast Cancer Res Treat; 2004 Aug; 86(3):249-57. PubMed ID: 15567941
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
[TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: a phase I study.
Cortesi E; Grifalchi F; Ramponi S; Padovani A; Mancuso A; Paoluzzi L; Ferrau F; Oliva A
Anticancer Res; 2003; 23(2C):1961-6. PubMed ID: 12820487
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
10. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
13. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
[TBL] [Abstract][Full Text] [Related]
14. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
Airoldi M; Cattel L; Milla P; Pedani F; Garzaro M; Dosio F
Anticancer Res; 2008; 28(4C):2519-27. PubMed ID: 18751444
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.
Bourgeois H; Joly F; Pujade-Lauraine E; Cure H; Guastalla JP; Ferru A; Chabrun V; Chieze S; Tourani JM
Am J Clin Oncol; 2006 Aug; 29(4):399-404. PubMed ID: 16891870
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Rossi D; Baldelli AM; Casadei V; Fedeli SL; Alessandroni P; Catalano V; Giordani P; Ceccolini M; Graziano F; Catalano G
Anticancer Drugs; 2008 Aug; 19(7):733-7. PubMed ID: 18594216
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
19. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
Duska LR; Penson R; Supko JG; Finkelstein DM; Makastorsis T; Gallagher J; Borden K; Goodman A; Fuller AF; Nikrui N; Seiden MV
Clin Cancer Res; 1999 Jun; 5(6):1299-305. PubMed ID: 10389912
[TBL] [Abstract][Full Text] [Related]
20. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
